Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Patient-reported outcome (PRO) measures can provide valuable information in evaluating patients' health-related quality of life (HRQoL). Post hoc analysis of the AFTERCAB study was conducted to evaluate the HRQoL benefit of enzalutamide plus androgen deprivation therapy (ADT) compared to flutamide plus ADT for the treatment of patients with castration-resistant prostate cancer (CRPC) in Japan. METHODS: The open-label AFTERCAB study was conducted from November 2016 to March 2020 in Japanese men aged ≥ 20 years with asymptomatic or mildly symptomatic CRPC. Patients received enzalutamide plus ADT or flutamide plus ADT, respectively, as first-line alternative androgen therapy (AAT). HRQoL was analyzed through the Functional Assessment of Cancer Therapy-Prostate, EuroQoL 5-Dimension 5-Level instruments, Brief Pain Inventory-Short Form, and Brief Fatigue Inventory. The longitudinal changes in HRQoL, HRQoL deterioration based on minimally important difference (MID), and time to HRQoL deterioration were evaluated for first-line AAT. RESULTS: Overall, HRQoL between the enzalutamide and flutamide groups was similar during first-line treatment. No statistically significant HRQoL difference in change from baseline to week 61 (least square mean difference; p value) was observed. Furthermore, proportions of pain progression, symptom worsening, and HRQoL deterioration based on MID, were not significantly different between groups. CONCLUSIONS: The results were similar in all subscales of each PRO, demonstrating similar HRQoL deterioration based on MID criteria between the enzalutamide and flutamide groups.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
- Date Crossref
- 10/08/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Yokohama City University Medical Center Department of Urology and Renal Transplantation pays non établi dans la noticeÉtablissement de santé
-
Yokohama City University pays non établi dans la noticeUniversité ou école supérieure
-
Yokosuka Kyosai Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Harasanshin Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Sapporo Medical University Department of Biostatistics and Data Management pays non établi dans la noticeUniversité ou école supérieure
-
Juntendo University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Kagawa University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
The University of Osaka pays non établi dans la noticeUniversité ou école supérieure
-
Kyoto University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Keio University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Gunma University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Astellas Pharma (Japan) pays non établi dans la noticeEntreprise
Department of Urology and Renal Transplantation — Yokohama City University Medical Center, Yokohama City University et Department of Urology — Yokosuka Kyosai Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.